2022
Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchMeSH KeywordsChildCost-Benefit AnalysisEarly Detection of CancerGerm CellsHumansInfantInfant, NewbornLi-Fraumeni SyndromeNeonatal ScreeningTumor Suppressor Protein p53Young AdultConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2021
Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years
Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. JAMA Internal Medicine 2021, 181: 1665-1668. PMID: 34459853, PMCID: PMC8406208, DOI: 10.1001/jamainternmed.2021.4832.Peer-Reviewed Original ResearchComparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women
Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. Journal Of General Internal Medicine 2021, 37: 1870-1876. PMID: 34595682, PMCID: PMC8483166, DOI: 10.1007/s11606-021-07132-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreastBreast DensityBreast NeoplasmsCohort StudiesEarly Detection of CancerFemaleHumansInfantMammographyMass ScreeningMedicareUnited StatesConceptsWomen 75Older womenBreast cancerAdditional cancersSubsequent imagingWomen 67Stage ITime of diagnosisEarly-stage cancerHigh rateCancer detectionConclusionsBreast cancerPrior cancerPotential confoundersScreening outcomesHealth outcomesService beneficiariesComparative effectivenessScreening mammogramsAge groupsCancerLogistic regressionResultsOur studyWomenBreast tomosynthesisComparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old
Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old. Journal Of The National Cancer Institute 2021, 113: 1515-1522. PMID: 33822120, PMCID: PMC8757313, DOI: 10.1093/jnci/djab063.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiopsyBreastBreast NeoplasmsEarly Detection of CancerFemaleHumansMammographyMass ScreeningMiddle AgedConceptsHigher cancer detection rateCancer detection rateBreast cancer screeningCancer screeningScreening outcomesBreast cancer screening outcomesDigital breast tomosynthesisCancer screening outcomesPopulation-level adoptionReal-world cohortMultivariable logistic regressionHigher biopsy ratesPatient-level analysisPopulation health impactDetection rateIncident cancerClinical outcomesWomen 40Biopsy rateObservational studyComparative effectivenessLogistic regressionYoung womenPrivate health insurersWomenUnderstanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. Medical Care 2021, 59: 437-443. PMID: 33560712, PMCID: PMC8611614, DOI: 10.1097/mlr.0000000000001506.Peer-Reviewed Original Research
2020
Breast Cancer Screening and Health Care Costs—Reply
Kunst N, Gross CP. Breast Cancer Screening and Health Care Costs—Reply. JAMA Internal Medicine 2020, 180: 1553-1554. PMID: 32777026, DOI: 10.1001/jamainternmed.2020.2355.Peer-Reviewed Case Reports and Technical NotesUse and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Internal Medicine 2020, 180: 799-801. PMID: 32202606, PMCID: PMC7147248, DOI: 10.1001/jamainternmed.2020.0262.Peer-Reviewed Original Research